top
Search terms
Results 1 - 10 of 19 - ordered by :
Pages: 1 2
Eurointervention

Matos D., Teles R., Almeida M., Mesquita J., Freitas P., Baptista J., Ribeiras R., Neves J., Mesquita Gabriel H., Vale N., Guerreiro S., Mendes M. AIMS To study which is the best antithrombotic ...

Date : 06/05/2016 Item size : 30696 bytes
Eurointervention

EuroIntervention Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score Department for Coagulation Disorders, Skane ...

Date : 26/10/2012 Item size : 35329 bytes
Eurointervention

Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. Dewilde W., Ten Berg JM, Trial design: WOEST Trial: What is the Optimal antiplatElet & ...

Date : 15/01/2010 Item size : 35995 bytes
Epeuropace

Warfarin, the most commonly applied VKA, reduces the stroke risk by 64%.1 The major drawbacks of VKA therapy include the risk of bleeding, especially intracranial haemorrhage, many food and drugdrug ...

Europace, Review, T. Lewalter, P. Kanagaratnam, B. Schmidt, M. Rosenqvist, J. E. Nielsen-Kudsk, R. Ibrahim, B. A. Albers, A. J. Camm

Date : 01/05/2014
Epeuropace

When a clinician has to decide on use of antithrombotic drugs in the setting of a patient affected by atrial fibrillation (AF) experiencing an acute coronary syndrome (ACS), the difficult task is ...

Europace, Editorial, Giuseppe Boriani, Deirdre A. Lane, Stephan Windecker, Kurt Huber, Paulus Kirchhof, Gregory Y.H. Lip

Date : 01/09/2015
Epeuropace

Dual antiplatelet therapy, in contrast, is recommended after coronary artery stenting to reduce the increased risk of stent thrombosis.3 Oral anticoagulant therapy is less effective after stenting,4 ...

Europace, Editorial, Francisco Marín, Paulus Kirchhof, Gregory Y.H. Lip

Date : 01/07/2009
Epeuropace

Abstract This EP Wire surveyed clinical practice with regard to the use of antithrombotic therapy in relation to device implantation (pacemakers, ICT, resynchronization therapy) and atrial ...

Europace, EP WIRE, Gregory Y.H. Lip, Alessandro Proclemer, Nikolaus Dagres, Maria Grazia Bongiorni, Thorsten Lewalter, Carina Blomstrom-Lundqvist

Date : 01/05/2012
Epeuropace

Abstract Aims The meta-analysis was to assess the safety and efficacy of periprocedural antithrombotic therapy and to evaluate the risk factors potentially associated with bleeding among patients ...

Europace, Pacing and resynchronization therapy, Xiaowei Yang, Zhongsu Wang, Yong Zhang, Xiangcui Yin, Yinglong Hou

Date : 01/07/2015
Ehjournal

The interface between recurrent thrombotic arterial events and the potential bleeding hazards of antithrombotic treatment after an acute coronary syndrome (ACS) occupies a central position in the ...

European Heart Journal, Armstrong, Paul W., Harrington, Robert A.

Date : 01/10/2012 Item size : 139115 bytes
Ehjournal

[...]clinical trials of antithrombotic therapy in patients with AF have rightly included bleeding events as part of the composite primary endpoint, as treatment decisions should be based upon net ...

European Heart Journal, Lane, Deirdre A., Lip, Gregory Y.H.

Date : 01/09/2010